Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 61
Filtrar
1.
Hepatol Commun ; 8(6)2024 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-38727682

RESUMEN

BACKGROUND: Hepatoblastoma and HCC are the most common malignant hepatocellular tumors seen in children. The aim of this study was to develop a liquid biopsy test for circulating tumor cells (CTCs) for these tumors that would be less invasive and provide real-time information about tumor response to therapy. METHODS: For this test, we utilized indocyanine green (ICG), a far-red fluorescent dye used clinically to identify malignant liver cells during surgery. We assessed ICG accumulation in cell lines using fluorescence microscopy and flow cytometry. For our CTC test, we developed a panel of liver tumor-specific markers, including ICG, Glypican-3, and DAPI, and tested it with cell lines and noncancer control blood samples. We then used this panel to analyze whole-blood samples for CTC burden with a cohort of 15 patients with hepatoblastoma and HCC and correlated with patient characteristics and outcomes. RESULTS: We showed that ICG accumulation is specific to liver cancer cells, compared to nonmalignant liver cells, non-liver solid tumor cells, and other nonmalignant cells, and can be used to identify liver tumor cells in a mixed population of cells. Experiments with the ICG/Glypican-3/DAPI panel showed that it specifically tagged malignant liver cells. Using patient samples, we found that CTC burden from sequential blood samples from the same patients mirrored the patients' responses to therapy. CONCLUSIONS: Our novel ICG-based liquid biopsy test for CTCs can be used to specifically detect and quantify CTCs in the blood of pediatric patients with liver cancer.


Asunto(s)
Carcinoma Hepatocelular , Hepatoblastoma , Verde de Indocianina , Neoplasias Hepáticas , Células Neoplásicas Circulantes , Humanos , Células Neoplásicas Circulantes/patología , Biopsia Líquida , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/patología , Niño , Femenino , Masculino , Preescolar , Hepatoblastoma/sangre , Hepatoblastoma/patología , Carcinoma Hepatocelular/sangre , Carcinoma Hepatocelular/patología , Línea Celular Tumoral , Biomarcadores de Tumor/sangre , Lactante , Adolescente , Colorantes
2.
J Pediatr Hematol Oncol ; 46(4): 206-210, 2024 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-38551915

RESUMEN

Hepatoblastoma is the most common liver malignancy in children. Treatment typically involves surgery and cisplatin-based chemotherapy. After therapy completion, children undergo repetitive surveillance imaging to screen for relapse, which occurs in <12% of cases. Monitoring for relapse has gradually shifted to serial determination of serum alpha-fetoprotein (AFP) alone as most cases have AFP elevation at the time of relapse. Little primary data supports, such a practice, however, and herein we present both our institutional experience with relapsed hepatoblastoma and a careful review of published literature on this topic. While serial AFP monitoring may suffice for most patients, certain clinical characteristics should give pause to the practitioner, when considering posttreatment monitoring with serum AFP alone.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Recurrencia Local de Neoplasia , alfa-Fetoproteínas , Humanos , alfa-Fetoproteínas/análisis , alfa-Fetoproteínas/metabolismo , Hepatoblastoma/sangre , Hepatoblastoma/diagnóstico , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/diagnóstico , Recurrencia Local de Neoplasia/sangre , Recurrencia Local de Neoplasia/diagnóstico , Recurrencia Local de Neoplasia/patología , Masculino , Femenino , Preescolar , Biomarcadores de Tumor/sangre , Lactante , Niño
3.
Pediatr Blood Cancer ; 67(11): e28594, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32881242

RESUMEN

Driver mutations in the CTNNB1 gene (encoding ß-catenin) are a hallmark of sporadic hepatoblastoma (HBL). Our results show that CTNNB1 circulating tumour DNA (ctDNA) is readily detected in patients diagnosed with localised HBL, with serial sampling along the course of therapy and follow up providing a sensitive mechanism to monitor tumour dynamics and response to treatment. This exciting potential for CTNNB1 ctDNA to serve as a biomarker for treatment response in HBL holds clinical value, and requires assessment in a larger cohort of mixed tumour stages and recurrent disease.


Asunto(s)
Biomarcadores de Tumor/genética , ADN Tumoral Circulante/sangre , ADN de Neoplasias/genética , Hepatoblastoma/diagnóstico , Neoplasias Hepáticas/diagnóstico , Mutación , beta Catenina/genética , Biomarcadores de Tumor/sangre , ADN Tumoral Circulante/genética , ADN de Neoplasias/sangre , Estudios de Seguimiento , Hepatoblastoma/sangre , Hepatoblastoma/genética , Humanos , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/genética , Pronóstico , Estudios Prospectivos , beta Catenina/sangre
4.
J Pediatr ; 225: 80-89.e4, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32470475

RESUMEN

OBJECTIVES: To evaluate the cost-effectiveness of screening children born at extremely low birth weight (ELBW) for hepatoblastoma using serial serum alpha-fetoprotein measurements. STUDY DESIGN: We created a decision tree to evaluate the cost effectiveness of screening children born at ELBW between 3 and 48 months of age compared with current standard of care (no screening). Our model used discounted lifetime costs and monetary benefits in 2018 US dollars, based on estimates in the published literature. The effects of uncertainty in model parameters were also assessed using univariate sensitivity analyses, in which we changed the values for one parameter at a time to assess the effect on the estimated incremental cost-effectiveness ratio. RESULTS: For the estimated 55 699 children born at ELBW in the US each year, this screening is associated with 77.7 additional quality-adjusted life-years (QALYs) at a cost of $8.7 million. This results in an incremental cost-effectiveness ratio of about $112 000/QALY, which is considered cost effective from a US societal perspective. For children diagnosed with hepatoblastoma, our model finds that the screening regimen is associated with a 10.1% increase in survival, a 4.18% increase in expected QALYs, and a $245 184 decrease in expected cost. CONCLUSIONS: Screening ELBW children for hepatoblastoma between 3 and 48 months of age dominates the alternative and is cost effective from a societal perspective.


Asunto(s)
Hepatoblastoma/diagnóstico , Hepatoblastoma/epidemiología , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/epidemiología , Tamizaje Neonatal/economía , Tamizaje Neonatal/métodos , alfa-Fetoproteínas/análisis , Niño , Preescolar , Análisis Costo-Beneficio , Árboles de Decisión , Costos de la Atención en Salud , Hepatoblastoma/sangre , Humanos , Incidencia , Lactante , Recien Nacido con Peso al Nacer Extremadamente Bajo , Recién Nacido , Neoplasias Hepáticas/sangre , Años de Vida Ajustados por Calidad de Vida , Estados Unidos
5.
Cancer ; 126(13): 3114-3121, 2020 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-32320050

RESUMEN

BACKGROUND: Constitutional or somatic mosaic epimutations are increasingly recognized as a mechanism of gene dysregulation resulting in cancer susceptibility. Beckwith-Wiedemann syndrome is the cancer predisposition syndrome most commonly associated with epimutation and is extremely variable in its phenotypic presentation, which can include isolated tumors. Because to the authors' knowledge large-scale germline DNA sequencing studies have not included methylation analysis, the percentage of pediatric cancer predisposition that is due to epimutations is unknown. METHODS: Germline methylation testing at the 11p15.5 locus was performed in blood for 24 consecutive patients presenting with hepatoblastoma (3 patients) or Wilms tumor (21 patients). RESULTS: Six individuals with Wilms tumor and 1 patient with hepatoblastoma were found to have low-level gain of methylation at imprinting control 1, and a child with hepatoblastoma was found to have loss of methylation at imprinting control 2. The loss of methylation at imprinting control 2 was found to be maternally inherited, despite not being associated with any detectable genomic alteration. CONCLUSIONS: Overall, 33% of patients (8 of 24 patients) with Wilms tumor or hepatoblastoma were found to have an epigenetic susceptibility that was detectable in the blood. It is interesting to note that low-level gain of methylation at imprinting control 1 predominantly was detected in females with bilateral Wilms tumors. Further studies in larger cohorts are needed to determine the efficacy of testing all patients with Wilms tumor or hepatoblastoma for 11p15.5 epimutations in the blood as part of DNA analysis because this hallmark of predisposition will not be detected by sequencing-based approaches and detecting a cancer predisposition may modify treatment.


Asunto(s)
Síndrome de Beckwith-Wiedemann/sangre , Metilación de ADN/genética , Impresión Genómica/genética , Hepatoblastoma/sangre , Tumor de Wilms/sangre , Adolescente , Adulto , Síndrome de Beckwith-Wiedemann/genética , Síndrome de Beckwith-Wiedemann/patología , Niño , Preescolar , Cromosomas Humanos Par 11/genética , Femenino , Predisposición Genética a la Enfermedad , Mutación de Línea Germinal/genética , Hepatoblastoma/genética , Hepatoblastoma/patología , Humanos , Lactante , Masculino , Proteínas de Neoplasias/genética , Tumor de Wilms/genética , Tumor de Wilms/patología , Adulto Joven
6.
Cancer Chemother Pharmacol ; 82(2): 361-365, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29922990

RESUMEN

PURPOSE: Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug monitoring in a 2-week-old neonate with localized hepatoblastoma. METHODS: Cisplatin concentrations were determined in plasma and ultrafiltrate samples collected on each of six cycles of a monotherapy regimen, beginning with a dose of 1.6 mg/kg at 16 days of age. Pharmacokinetic data were analyzed to generate clearance (CL) and area under the curve (AUC0-∞) for each administration. Toxicity and clinical response were monitored. RESULTS: The first cisplatin dose (1.6 mg/kg) resulted in an AUC0-∞ of 535 µg/mL · min, was well tolerated and associated with a good response. This AUC was, therefore, considered as an appropriate target for this patient. Increases in cisplatin CL were observed across consecutive treatment cycles, and, therefore, dose was gradually increased to finally reach 2.5 mg/kg on the sixth cycle. Treatment was well tolerated over the six courses and resulted in a good response, with the patient remaining in remission at 15 months. Cisplatin CL was significantly correlated to age (p = 0.013) and weight (p = 0.013). CONCLUSIONS: Our study provides useful data on the pharmacokinetics of cisplatin monotherapy in neonates treated within the first few weeks of life. These data provide a reference point to support clinicians in determining appropriate dosing regimens for neonates and support the implementation of therapeutic drug monitoring in such challenging patients.


Asunto(s)
Cisplatino/administración & dosificación , Cisplatino/sangre , Hepatoblastoma/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Antineoplásicos/administración & dosificación , Antineoplásicos/sangre , Monitoreo de Drogas/métodos , Femenino , Hepatoblastoma/sangre , Humanos , Recién Nacido , Neoplasias Hepáticas/sangre
7.
Am J Pathol ; 188(8): 1895-1909, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29920228

RESUMEN

Hepatoblastoma (HB) is the most common pediatric liver malignant tumor. Previously, we reported co-activation of ß-catenin and Yes-associated protein-1 (YAP1) in 80% of HB. Hepatic co-expression of active ß-catenin and YAP1 via sleeping beauty transposon/transposase and hydrodynamic tail vein injection led to HB development in mice. Here, we identify lipocalin 2 (Lcn2) as a target of ß-catenin and YAP1 in HB and show that serum Lcn2 values positively correlated with tumor burden. Lcn2 was strongly expressed in HB tumor cells in our mouse model. A tissue array of 62 HB cases showed highest LCN2 expression in embryonal and lowest in fetal, blastemal, and small cell undifferentiated forms of HB. Knockdown of LCN2 in HB cells had no effect on cell proliferation but reduced NF-κB reporter activity. Next, liver-specific Lcn2 knockout (KO) mice were generated. No difference in tumor burden was observed between Lcn2 KO mice and wild-type littermate controls after sleeping beauty transposon/transposase and hydrodynamic tail vein injection delivery of active YAP1 and ß-catenin, although Lcn2 KO mice with HB lacked any serum Lcn2 elevation, demonstrating that transformed hepatocytes are the source of serum Lcn2. More blastemal areas and inflammation were observed within HB in Lcn2 KO compared with wild-type tumors. In conclusion, Lcn2 expressed in hepatocytes appears to be dispensable for the pathogenesis of HB. However, transformed hepatocytes secrete serum Lcn2, making Lcn2 a valuable biomarker for HB.


Asunto(s)
Biomarcadores de Tumor/sangre , Hepatoblastoma/patología , Hepatocitos/patología , Lipocalina 2/sangre , Proteínas Adaptadoras Transductoras de Señales/metabolismo , Animales , Proteínas de Ciclo Celular , Proliferación Celular , Hepatoblastoma/sangre , Hepatocitos/metabolismo , Humanos , Ratones , Ratones Noqueados , FN-kappa B/metabolismo , Fosfoproteínas/metabolismo , Transducción de Señal , Factores de Transcripción , Carga Tumoral , Proteínas Señalizadoras YAP
8.
Pediatr Transplant ; 22(5): e13221, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29761829

RESUMEN

LT is a practical therapeutic alternative for unresectable hepatoblastoma; however, deciding when to perform LT is difficult. The aim of this study was to optimize the timing of LT for hepatoblastoma using pretransplant trends in AFP levels. Trends in pretransplant AFP levels and their influence on post-transplant outcomes were retrospectively evaluated. All patients who underwent living donor LT for hepatoblastoma in our institution since 2002 were included. Variables analyzed included history of prior tumor resection, pretransplant AFP responses to chemotherapy, metastatic disease at diagnosis, and post-transplant chemotherapy. Eight patients (seven boys and one girl; median age, 35 months; range, 15 months-12 years) were transplanted. The overall post-transplant recurrence-free survival rate was 62.5% (5/8) with a mean follow-up of 77 months. Patients with post-transplant recurrence showed a 0.573 log increase in AFP levels after the last chemotherapy session before LT. This was significantly higher than the 0.279 log decrease observed in patients without post-transplant recurrence (P = .024). Because the AFP response cannot be accurately predicted before each cycle of chemotherapy, it may be appropriate to perform LT when AFP levels do not decrease after the last cycle and before they are found to be elevated again.


Asunto(s)
Hepatoblastoma/cirugía , Neoplasias Hepáticas/cirugía , Trasplante de Hígado , Recurrencia Local de Neoplasia/diagnóstico , alfa-Fetoproteínas/metabolismo , Niño , Preescolar , Femenino , Estudios de Seguimiento , Hepatoblastoma/sangre , Hepatoblastoma/diagnóstico , Humanos , Lactante , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/diagnóstico , Trasplante de Hígado/métodos , Donadores Vivos , Masculino , Recurrencia Local de Neoplasia/sangre , Recurrencia Local de Neoplasia/etiología , Periodo Preoperatorio , Estudios Retrospectivos , Resultado del Tratamiento
9.
Pediatr Blood Cancer ; 65(1)2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28921839

RESUMEN

BACKGROUND: The purpose of this study was to evaluate clinical characteristics, treatment, and survival of children, who were diagnosed with hepatoblastoma (HB) in their first 6 months of age, enrolled in the SIOPEL 2 and 3 protocols. METHODS: Seventy-nine patients, treated between 1994 and 2006, were analyzed after stratification into three age groups: <1 month, between 1 and 3 months, and between 3 and 6 months. All received preoperative chemotherapy. RESULTS: Clinical characteristics were similar in both trials: 4 patients had pulmonary metastases at diagnosis, 4 had α-fetoprotein <100 ng/ml, 68 were operated by partial hepatectomy, and 7 received liver transplant. Chemotherapy courses were delayed in 8.5%, 8.4%, and 11.8% of cycles in the three groups. Doses were calculated according to weight for children <5 and 5-10 kg, and further reduced in 18.1%, 6.8%, and 5.9% of cycles. Acute toxicity was manageable. Long-term hearing loss was the major problem at follow-up occurring in two-thirds of children. Ten patients experienced progression or relapse, and 5 of 10 died. After a median follow-up of 5.6 years, the 5-year overall survival (OS) and event-free survival (EFS) were 91% (95% confidence interval [CI]: 84-96%) and 87% (95% CI: 78-92%), respectively. CONCLUSIONS: The 5-year OS and EFS of children <6 months of age affected by HB seem to be similar to those documented in the elder children. Dose reduction does not seem to jeopardize the long-term outcome and may explain the lower toxicity profile. Ototoxicity though appears as high as in the whole population of SIOPEL 2 and 3. The treatment for these children should be further explored in international studies, particularly focusing on prevention of hearing loss.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Neoplasias Pulmonares , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Hepatectomía , Hepatoblastoma/sangre , Hepatoblastoma/mortalidad , Hepatoblastoma/patología , Hepatoblastoma/terapia , Humanos , Lactante , Recién Nacido , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/terapia , Trasplante de Hígado , Neoplasias Pulmonares/sangre , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/terapia , Masculino , Metástasis de la Neoplasia , Tasa de Supervivencia
10.
Sci Rep ; 7: 45932, 2017 04 05.
Artículo en Inglés | MEDLINE | ID: mdl-28378832

RESUMEN

Hepatoblastoma (HB) is the most common primary liver cancer in children. The conventional serum marker for HB, alpha-fetoprotein (AFP), has its limitations. Novel serum markers need to be explored. Glypican 3 (GPC3) has been reported to be an excellent histological immunomarker for HB. However, the clinical value of serum GPC3 in patients with HB is unknown. A total of 184 serum samples were tested for both GPC3 by ELISA, and AFP by immunometric assay. Of these, 134 were from 32 patients with HB at three treatment stages, 30 from age-matched patients with benign hepatobiliary disorders (BHD) and 20 from age-matched "normal controls"(NC). We found that the GPC3 levels in HB pretreatment group were significantly higher than those in NC group and HB remission group but not statistically different from those in BHD group and HB during treatment group. In contrast, AFP showed significant differences among different groups. The areas under the receiver operating curve (AUROC) value, sensitivity and specificity of GPC3 for HB pretreatment group versus all controls were all significantly lower than those of AFP. Serum GPC3 levels were not associated with prognostic parameters. We concluded that GPC3 is inferior to AFP as a serum marker for HB.


Asunto(s)
Biomarcadores de Tumor/sangre , Glipicanos/sangre , Hepatoblastoma/sangre , Neoplasias Hepáticas/sangre , Adolescente , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática , Femenino , Hepatoblastoma/diagnóstico , Humanos , Lactante , Neoplasias Hepáticas/diagnóstico , Masculino , Pronóstico , Curva ROC , alfa-Fetoproteínas/análisis
11.
J Pediatr Surg ; 52(4): 618-624, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28277300

RESUMEN

PURPOSE: The aim of this study is to identify the diagnostic values of serum exosomal miRNA-34s of patients with HB in a large Asian group and explore the prognostic value of the exosomal miRNA-34s panel compared with other risk factors. METHODS: We retrospectively reviewed 89 children with HB. Among these patients, 63 patients were included as training group to build the diagnostic model for HB. 26 patients were defined as the validation group. The expressions of miRNA-34s were detected by real-time PCR. The comparison of diagnostic and prognostic performance of serum exosomal miRNA-34s was measured using the area under ROC curve (AUC). RESULTS: For patients in the training group, expression of miRNA-34a, miRNA-34b and miRNA-34c was significantly lower in patients with HB compared with control group in serum exosomes. Between HB training group and the control group, exosomal miRNA-34a, miRNA-34b and miRNA-34c had no significant differences compared with the AFP level in diagnosing HB. The performance of the exosomal miRNA-34s panel in differentiating the HB training group from the control group was superior to the AFP level. The value of the exosomal miRNA-34s panel in predicting prognosis of patients with HB was superior to other risk factors in both training group and validation group. CONCLUSIONS: In this study, we found that the expression of exosomal miRNA-34a, miRNA-34b and miRNA-34c was significantly lower in patients with HB compared with the control group, and we confirmed the exosomal miRNA-34s panel could be defined as a diagnostic and prognostic biomarker for patients with HB. LEVEL OF EVIDENCE: Level II. TYPE OF STUDY: Retrospective Study.


Asunto(s)
Biomarcadores de Tumor/sangre , Exosomas , Hepatoblastoma/diagnóstico , Neoplasias Hepáticas/diagnóstico , MicroARNs/sangre , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Estudios de Seguimiento , Hepatoblastoma/sangre , Hepatoblastoma/genética , Humanos , Lactante , Recién Nacido , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/genética , Masculino , Pronóstico , Reacción en Cadena en Tiempo Real de la Polimerasa , Estudios Retrospectivos , Factores de Riesgo
12.
Exp Clin Transplant ; 15(Suppl 1): 50-52, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28260432

RESUMEN

OBJECTIVES: Our aim was to analyze our experience with orthotopic liver transplant for hepatoblastoma patients. MATERIALS AND METHODS: We performed a single-center retrospective analysis of 6 orthotopic liver transplant cases in children with hepatoblastoma from 2001 to March 2015. We evaluated patient demographic features, pretreatment extent of disease stage, type of transplant, change in serum alpha-fetoprotein levels, complications, and follow-up results. RESULTS: Orthotopic liver transplant was performed for pretreatment extent of disease stage III with a central location (n = 3) and pretreatment extent of disease stage IV (n = 3). All children underwent living-donor orthotopic liver transplant. Postoperative serum alpha-fetoprotein levels remained below 10 ng/mL during the follow-up period in 3 patients who were free of recurrences or metastases. Five patients were free of tumor recurrences at a median follow-up of 29.9 months. CONCLUSIONS: The limited number of cases we present without long-term follow-up of orthotopic liver transplant for unresectable hepatoblastoma seemed to show good clinical results.


Asunto(s)
Hepatoblastoma/cirugía , Neoplasias Hepáticas/cirugía , Trasplante de Hígado , Factores de Edad , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Hepatoblastoma/sangre , Hepatoblastoma/patología , Humanos , Lactante , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/patología , Trasplante de Hígado/métodos , Donadores Vivos , Masculino , Estadificación de Neoplasias , Estudios Retrospectivos , Factores de Tiempo , Tomografía Computarizada por Rayos X , Resultado del Tratamiento , Turquía , alfa-Fetoproteínas/metabolismo
14.
Pediatr Int ; 59(2): 159-162, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27400853

RESUMEN

BACKGROUND: Extremely low-birthweight infants (ELBWI) are at greater risk of developing hepatoblastoma than are normal-weight infants. Serum α-fetoprotein (AFP) plays an important role as a tumor marker in the diagnosis of hepatoblastoma, therefore the aim of this study was to determine the changes in serum AFP concentration after birth in ELBWI. METHODS: Data were obtained for infants born between January 2005 and March 2008 with birthweight <1000 g who were followed up at Gunma Children's Medical Center with clinical examinations, including monitoring of the development of hepatoblastoma. The relationship between serum AFP concentration and age was analyzed up to 730 days after birth. RESULTS: Overall, 95 serum AFP measurements were obtained from 23 infants 30-730 days of age, with gestational age 24-32 weeks, and birthweight 498-982 g. Log10 (AFP [ng/mL]) was significantly correlated with log10 (age [days]) (r = -0.961, P = 0.000, n = 95), with the following regression formula: log10 (AFP [ng/mL]) = 11.063 - 3.752 log10 (age [days]) (adjusted R2  = 0.923, n = 95). The standard error of the estimate, mean log10 (age [days]), and the sum of squares for log10 (age [days]) were 0.363, 2.503, and 10.579, respectively. CONCLUSIONS: A correlation was found between serum AFP concentration and age in ELBWI, and the 95%CI of serum AFP concentration was determined for ELBWI up to 2 years after birth.


Asunto(s)
Hepatoblastoma/diagnóstico , Recien Nacido con Peso al Nacer Extremadamente Bajo/sangre , Enfermedades del Prematuro/diagnóstico , Neoplasias Hepáticas/diagnóstico , alfa-Fetoproteínas/metabolismo , Factores de Edad , Preescolar , Femenino , Estudios de Seguimiento , Hepatoblastoma/sangre , Humanos , Lactante , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/sangre , Neoplasias Hepáticas/sangre , Masculino , Valores de Referencia , Estudios Retrospectivos
15.
Medicine (Baltimore) ; 96(47): e8798, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29381980

RESUMEN

OBJECTIVES: Hepatoblastoma (HB) is the most common pediatric liver malignancy, typically affecting children within the first 4 years of life. However, only a few validated blood biomarkers are used in clinical evaluation. The current study explored the clinical application and significance of D-dimer levels in patients with HB. METHOD: Forty-four patients with HB were included in this retrospective study. D-dimer and plasma fibrinogen levels were examined, and their correlation with other clinical features was analyzed. D-dimer and plasma fibrinogen levels were examined between HB and other benign hepatic tumors. RESULTS: D-dimer levels were significantly associated with high-risk HB features, such as advanced stage and high α-fetoprotein (AFP) levels. Higher D-dimer levels were observed in stage 4 patients compared with stage 1/2/3 patients (P = .028). Higher D-dimer levels were also observed in patients with higher AFP levels before chemotherapy compared with patients with lower AFP levels after chemotherapy (P< 0.001). In addition, higher D-dimer levels were observed in HB compared with other benign hepatic tumors such as hepatic hemangioma and hepatocellular adenoma (P = .012). No significant difference in D-dimer levels was found between sex (P = .503) and age (≥12 vs <12 months, P = .424). There was no significant difference in plasma fibrinogen levels between sex or age and high-risk HB features, such as advanced stage and high AFP levels. CONCLUSIONS: Elevated D-dimer levels could be a useful determinant biomarker for high-risk features in patients with HB. This finding also supports the clinical application of D-dimer in HB.


Asunto(s)
Productos de Degradación de Fibrina-Fibrinógeno/análisis , Hepatoblastoma/sangre , Neoplasias Hepáticas/sangre , Biomarcadores de Tumor/sangre , Niño , Preescolar , Femenino , Fibrinógeno/análisis , Humanos , Lactante , Recién Nacido , Masculino , Estudios Retrospectivos , alfa-Fetoproteínas/análisis
16.
Zhongguo Dang Dai Er Ke Za Zhi ; 18(12): 1205-1210, 2016 Dec.
Artículo en Chino | MEDLINE | ID: mdl-27974108

RESUMEN

OBJECTIVE: To screen and identify serum biomarkers for childhood hepatoblastoma (HB). METHODS: The serum samples from 30 children with hepatoblastoma (HB), 20 children with systemic inflammatory response syndrome, and 20 normal children were treated with magnetic bead-based weak cation exchange chromatography. The platform of surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS) was used to eliminate the interference of inflammatory factors and to screen out the differentially expressed proteins in serum between tumor group and normal group. After the purification and separation of target proteins were performed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, matrix-assisted laser desorption/ionization-time of flight-mass spectrometry was used to determine their amino acid sequences. The SwissProt database was searched for matched proteins. Finally, real-time PCR and ELISA were used to verify and measure the expression of target proteins. RESULTS: After SELDI-TOF-MS was used for screening and elimination of the interference of inflammatory factors, a differentially expression protein with a mass-to-charge ratio of 9 348 Da was found in serum between HB group and normal group, and the HB group had significantly lower expression of this protein than the normal group (p<0.05). This protein was identified as apolipoprotein A-1 (Apo A-I). Real-time PCR and ELISA verified the low mRNA and protein expression of Apo A-I in serum in the HB group and high expression in serum in the normal group. CONCLUSIONS: Apo A-I can be used as a non-inflammatory protein marker for HB and has a certain value in the early diagnosis of HB.


Asunto(s)
Apolipoproteína A-I/sangre , Biomarcadores/sangre , Detección Precoz del Cáncer , Hepatoblastoma/diagnóstico , Neoplasias Hepáticas/diagnóstico , Apolipoproteína A-I/genética , Preescolar , Femenino , Hepatoblastoma/sangre , Humanos , Lactante , Neoplasias Hepáticas/sangre , Masculino , Reacción en Cadena en Tiempo Real de la Polimerasa , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
17.
Pediatr Surg Int ; 32(11): 1059-1065, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27601233

RESUMEN

BACKGROUND: Hepatoblastoma (HB) is the most common primary malignant tumor of the liver in young children. The aim of this study is to identify the diagnostic and prognostic values of serum exosomal miR-21 in Chinese patients with HB. METHODS: We retrospectively reviewed 32 children with HB. The expressions of miR-21 were detected by real-time PCR. The comparison of diagnostic performance of plasmatic, exosomal miR-21 and AFP levels was measured using the Area Under ROC Curve. RESULTS: For patients in HB group, miR-21 concentration was significantly higher in the exosomes compared with the exosome-depleted supernatants and whole plasma. Expression of miR-21 was significantly higher in patients with HB compared with control group in both plasma and exosomes. With respect to the diagnosis of patients with HB, exosomal miR-21 was significantly more accurate compared with the Alpha-fetoprotein levels. Moreover, exosomal miR-21 was an independent predictor of Even-free survival for patients with HB. CONCLUSIONS: In this study, we found that expression of miR-21 was significantly higher in patients with HB compared with control group in both plasma and exosomes, and we confirmed that exosomal miR-21 could be defined as a diagnostic and prognostic biomarker for patients with HB.


Asunto(s)
Hepatoblastoma/sangre , Hepatoblastoma/genética , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/genética , MicroARNs/sangre , MicroARNs/genética , Biomarcadores de Tumor/sangre , Preescolar , China , Exosomas/genética , Exosomas/metabolismo , Femenino , Hepatoblastoma/diagnóstico , Humanos , Lactante , Neoplasias Hepáticas/diagnóstico , Masculino , Pronóstico , Curva ROC , Reacción en Cadena en Tiempo Real de la Polimerasa , Estudios Retrospectivos
18.
J Pediatr Gastroenterol Nutr ; 63(2): 188-94, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27457778

RESUMEN

OBJECTIVES: Surveillance of hepatic nodules for malignant transformation to hepatocellular carcinoma is important in the monitoring of patients with biliary atresia (BA). To date, only 2 published case reports describe the finding of hepatoblastoma (HB) in this setting. The present study aimed to investigate this association of HB and BA, and to assess the utility of alpha-fetoprotein (aFP) as a marker in the diagnosis. METHODS: A retrospective study of all patients who underwent isolated liver transplantation (LTx) for the primary diagnosis of BA at a single center, between January 1999 and June 2014, was conducted. Patient demographics, pre-LTx aFP levels, and histologic examination of native liver explants were reviewed. RESULTS: One hundred two (44% men, median age 11 months) patients underwent LTx for BA. Two (2%) explants examinations were confirmatory for concomitant HB; both patients had abnormally elevated aFP. Overall, 56 (55%) patients had available pre-LTx aFP levels. Recipients with persistently abnormal aFP levels (n = 20, 36%) were older at hepatoportoenterostomy (107 vs 68 days, P = 0.02) and younger at LTx surgery (359 vs 1713 days, P < 0.01), compared to patients with constantly normal levels (n = 24, 43%). CONCLUSIONS: In our cohort, HB was found to coexist in approximately 2% of patients with BA undergoing LTx, far exceeding the hypothetical anticipated incidence of 1:10 billion for the concomitant diagnoses. Elevated serum aFP levels may be sensitive but not specific for HB in this context. Further research is required to identify specific mechanisms and risk factors.


Asunto(s)
Atresia Biliar/complicaciones , Hepatoblastoma/etiología , Neoplasias Hepáticas/etiología , Trasplante de Hígado , alfa-Fetoproteínas/metabolismo , Atresia Biliar/cirugía , Femenino , Estudios de Seguimiento , Hepatoblastoma/sangre , Hepatoblastoma/diagnóstico , Hepatoblastoma/epidemiología , Humanos , Lactante , Recién Nacido , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/epidemiología , Masculino , Prevalencia , Estudios Retrospectivos , Factores de Riesgo , Sensibilidad y Especificidad
19.
Pediatr Transplant ; 20(3): 401-7, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-27012966

RESUMEN

LT from ABO-I donors requires preconditioning regimens to prevent postoperative catastrophic AMR. NAC for HBL is known to cause myelosuppression leading to a reduction in the number and function of lymphocytes. We investigated this chemotherapy-induced myelosuppression in HBL patients listed for LT from ABO-I donors with reference to the kinetics of B, T cells, and anti-ABO blood type isoagglutinin titers. Between 2005 and 2015, of the 319 patients who underwent LDLT at our institute, 12 were indicated for unresectable HBL. Three patients with unresectable HBL who underwent LDLT from ABO-I donors are included in this study. Immunosuppression consisted of a standard regime of tacrolimus and low-dose steroids as in ABO compatible/identical LDLT. No additional preoperative therapies for B-cell depletion were used. Absolute lymphocyte counts, lymphocyte subsets (including CD20+ B cells, CD3+CD4+ T cells and CD3+CD8+ T cells), and anti-ABO blood type isoagglutinin titers were measured before LDLT and postoperatively. The median age at diagnosis was 19 months (range, 3-31 months). The median follow-up was seven months (range, 6-15 months). The median interval from the last NAC to LDLT was 33 days (range, 25-52 days). The median interval from LDLT to adjuvant chemotherapy was 28 days (range, 22-36 days). The counts of CD20+ B cells before LDLT were depleted to median 5 cells/mm(3) (range, 0-6 cells/mm(3)). There was a transient rebound in the CD20+ B cell counts on day seven (maximum of 82 cells/mm(3)) followed by a decline starting at 14 days after LDLT that was sustained for the duration of adjuvant chemotherapy. Anti-ABO blood type isoagglutinin titers were lowered to between 1:1 and 1:16 before LDLT and remained low for the duration of follow-up in this study. All of the three patients remained in good health without either acute cellular or AMR after LDLT. The B-cell depletion that occurs after cisplatin-based chemotherapy for HBL may help accomplish safe ABO-I LDLT in children without the use of additional conditioning regimens for prevention of AMR.


Asunto(s)
Antineoplásicos/efectos adversos , Linfocitos B/efectos de los fármacos , Incompatibilidad de Grupos Sanguíneos , Hepatoblastoma/cirugía , Neoplasias Hepáticas/cirugía , Trasplante de Hígado/efectos adversos , Sistema del Grupo Sanguíneo ABO , Antígenos CD20/sangre , Linfocitos B/citología , Complejo CD3/sangre , Linfocitos T CD4-Positivos/citología , Linfocitos T CD8-positivos/citología , Quimioterapia Adyuvante/métodos , Preescolar , Cisplatino/uso terapéutico , Infecciones por Citomegalovirus/complicaciones , Femenino , Hepatoblastoma/sangre , Hepatoblastoma/tratamiento farmacológico , Humanos , Inmunidad Innata , Terapia de Inmunosupresión , Lactante , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/tratamiento farmacológico , Trasplante de Hígado/métodos , Donadores Vivos , Subgrupos Linfocitarios , Masculino , Riesgo , Rituximab/uso terapéutico , Tacrolimus/uso terapéutico , Acondicionamiento Pretrasplante , Resultado del Tratamiento
20.
Int J Mol Sci ; 16(6): 12669-85, 2015 Jun 04.
Artículo en Inglés | MEDLINE | ID: mdl-26053398

RESUMEN

The present study aimed to identify serum biomarkers for the detection of hepatoblastoma (HB). Serum samples were collected from 71 HB patients (stage I, n = 19; stage II, n = 19, stage III, n = 19; and stage IV, n = 14) and 23 age- and sex-matched healthy children. Differential expression of serum protein markers were screened using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS), and the target proteins were isolated and purified using HPLC and identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), SEQUEST, and bioinformatics analysis. Differential protein expression was confirmed by enzyme-linked immunosorbent analysis (ELISA). SELDI-TOF-MS screening identified a differentially expressed protein with an m/z of 9348 Da, which was subsequently identified as Apo A-I; its expression was significantly lower in the HB group as compared to the normal control group (1546.67 ± 757.81 vs. 3359.21 ± 999.36, respectively; p < 0.01). Although the expression level decreased with increasing disease stage, pair-wise comparison revealed significant differences in Apo A-I expression between the normal group and the HB subgroups (p < 0.01). ELISA verified the reduced expression of Apo A-I in the HB group. Taken together, these results suggest that Apo A-I may represent a serum protein biomarker of HB. Further studies will assess the value of using Apo A-I expression for HB diagnosis and staging.


Asunto(s)
Biomarcadores de Tumor/sangre , Proteínas Sanguíneas/análisis , Hepatoblastoma/diagnóstico , Neoplasias Hepáticas/diagnóstico , Proteómica/métodos , Estudios de Casos y Controles , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática , Femenino , Hepatoblastoma/sangre , Humanos , Neoplasias Hepáticas/sangre , Masculino , Estadificación de Neoplasias , Pronóstico , Análisis por Matrices de Proteínas , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...